💊 SGLT2i vs GLP-1 in Lupus Nephritis TriNetX evaluating the impact of GLP-1 agonists vs SGLT-2 inhibitors on outcomes of lupus nephritis 📊 GLP-1 use linked to better renal & CV outcomes in LN including: ⬇️ CKD progression ⬇️ Mortality ⬇️ Acute MI @RheumNow #ACR25 https://t.co/v4LgKFDt68